ストックスクリーナーアプリを入手
0.6014
7.49%
-0.0487
プレマーケット:
.61
0.0086
+1.43%
Humacyte Inc (HUMA) 最新ニュース
Investigation into Humacyte continues after FDA cites manufacturing violations and lawsuit proceeds. - Pluang
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Morningstar
Humacyte ATEV shows superiority in Phase 3 V012 study - scanx.trade
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - Moomoo
Humacyte (HUMA) Shares: Records a 7.28% Decrease to $0.68 on the Day; Next Session - vinanet.vn
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.25 - Moomoo
Humacyte (HUMA) Q2 2026 Earnings Call Transcript - AOL.com
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com Australia
Humacyte publishes Phase 3 trial results in Lancet journal - Investing.com
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - The Manila Times
Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results - TradingView
A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis - Stock Titan
Fresenius Medical Care stock trades close to recent NYSE levels as Humacyte stake sale draws attenti - Ad-hoc-news.de
MSN Money - MSN
Major Humacyte (HUMA) holder sells shares under 10b5‑1 plan - Stock Titan
Humacyte Announces First Symvess Implants in Arizona by Phoenix Vascular Surgeon Jeromy Brink - Quiver Quantitative
A bioengineered blood vessel is ready off the shelf for urgent surgery - Stock Titan
HC Wainwright Predicts Humacyte's Q3 Earnings (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
Humacyte earnings missed by $0.07, revenue fell short of estimates - Investing.com Nigeria
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women - Yahoo Finance
Humacyte Q2 Revenue Rises to $0.4 Million as Net Loss Narrows - Moomoo
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ... - Yahoo Finance Australia
Humacyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Humacyte, Inc. Q2 2026: Revenue $406K, EPS $(0.16) — 10-Q Summary - TradingView
Humacyte (NASDAQ: HUMA) logs $54.4M loss and flags going concern risk - Stock Titan
HUMA Q2 FY2026 earnings call - finance.biggo.com
Sutro Biopharma, Humacyte, CoreWeave - TradingView
Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results - MarketBeat
Humacyte stock maintained at Buy by BTIG on pipeline progress - Investing.com Canada
Humacyte Q2 Results: Sales Miss Estimate by 64%, Loss Widens - scanx.trade
Earnings call transcript: Humacyte misses Q2 2026 estimates as shares fall premarket - Investing.com Nigeria
Humacyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
HUMA: Q2 2026 marked clinical breakthroughs, commercial momentum, and robust financial positioning - TradingView
Transcript : Humacyte, Inc., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
HUMA: Breakthrough clinical results and commercial momentum position for growth and new launches in 2027 - TradingView
Humacyte Q2 Earnings Call Highlights - TradingView
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte, Inc. (HUMA) Q2 FY2026 earnings call transcript - Yahoo Finance
Form 8K Humacyte Inc For: 12 August By Investing.com - Investing.com Australia
HUMACYTE ($HUMA) Releases Q2 2026 Earnings - Quiver Quantitative
Form 8K Humacyte Inc For: 12 August - Investing.com India
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Humacyte reports Q2 2026: Product revenue $0.4M, net loss $36.8M, cash $80.3M - TradingView
Humacyte Reports Breakthrough V012 Dialysis Access Results, FDA Accepts CTEV IND, and Second-Quarter 2026 Financial Results - Quiver Quantitative
Humacyte Q2 revenue rises to $0.4 million as net loss narrows - Quiver Quantitative
BRIEF-Humacyte Q2 Operating Expenses USD 27.402 Million - TradingView
Humacyte (NASDAQ:HUMA): What Could Today’s commercial adoption and manufacturing Update Reveal? - Kalkine Media
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Expect - Yahoo Finance
Humacyte Inc (HUMA) Q2 2026 Earnings Report Preview: What To Exp - GuruFocus
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Humacyte Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Certain Stock Options of Humacyte, Inc. are subject to a Lock-Up Agreement Ending on 10-AUG-2026. - marketscreener.com
Humacyte to Announce 2026 Second Quarter Fina - Moomoo
Humacyte to Report Second Quarter 2026 Financial Results and Host Corporate Update Webcast on August 12 - Quiver Quantitative
0.46%
2.77%
大文字化:
|
ボリューム (24 時間):